InSphero Adds Chief Financial Officer to Senior Management Team
Schlieren, Switzerland, Oct 15, 2015 – Oliver Krähenbühl brings 25 years of finance experience in the technology industry, strengthens senior team at global leader in 3D cell culture.
InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of more organotypic 3D cell culture models, has appointed Oliver Krähenbühl to serve as Chief Financial Officer. Mr. Krähenbühl joins the InSphero senior management team having previously held CFO positions at HF Global Inc. New York, Canon, and JobCloud AG, the leading Swiss online professional recruiting company.
InSphero CEO and co-founder Dr. Jan Lichtenberg states the company “stands to benefit immediately from Oliver’s decades of experience, including 15 years at an executive management level and significant cross-Atlantic know-how. In Oliver we have gained a proven expert to guide us financially through our next phase of global trade and operational expansion, particularly following the recent securing of our Series C financing round. We are excited to have him as a member of our team.”
A native of Switzerland and a Swiss Certified Expert in International Accounting and Controlling, Mr. Krähenbühl earned his MBA at the University of Chicago - Booth School of Business. Prior to his previously held CFO positions, he served in various financial, systems integration and project management capacities at Hewlett Packard.
For more information about InSphero, visit www.insphero.com .
InSphero contact
Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
randy.strube@insphero.com
Dr. Jan Lichtenberg
CEO and co-founder
Phone +41 44 5150490
jan.lichtenberg@insphero.com
About InSphero
InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.
Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.
Follow us on Twitter and www.insphero.com.
InSphero Granted Hanging Drop Patent in United States
